1.84
+0.015(+0.82%)
Currency In USD
| Previous Close | 1.83 |
| Open | 1.82 |
| Day High | 1.89 |
| Day Low | 1.78 |
| 52-Week High | 2.89 |
| 52-Week Low | 1.36 |
| Volume | 317,384 |
| Average Volume | 578,050 |
| Market Cap | 50.79M |
| PE | -0.62 |
| EPS | -2.96 |
| Moving Average 50 Days | 1.93 |
| Moving Average 200 Days | 1.85 |
| Change | 0.02 |
If you invested $1000 in Fortress Biotech, Inc. (FBIO) 10 years ago, it would be worth $51.32 as of February 05, 2025 at a share price of $1.84. Whereas If you bought $1000 worth of Fortress Biotech, Inc. (FBIO) shares 5 years ago, it would be worth $51.76 as of February 05, 2025 at a share price of $1.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
GlobeNewswire Inc.
Jan 27, 2025 1:30 PM GMT
Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the benefit of vaccinating donors with Triplex to convey
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
GlobeNewswire Inc.
Jan 06, 2025 1:00 PM GMT
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium also retains ownership over any Priority Re
Fortress Biotech to Participate in October 2024 Investor Conferences
GlobeNewswire Inc.
Sep 26, 2024 12:30 PM GMT
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equ